摘要:
The invention relates to the identification of a tumor rejection antigen precursor. It has been established that preprocalcitonin protein functions as a tumor rejection antigen precursor, and is processed to at least one tumor rejection antigen. Complexes of the tumor rejection antigen and an MHC molecule are recognized by cytolytic T lymphocytes, and lysed.
摘要:
The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.
摘要:
The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
摘要:
L'invention est relative à des combinaisons de peptides portant des épitopes T de l'antigène préprocalcitonine, présentés par le CMH. Ces peptides sont utilisables en immunothérapie anti-tumorale.
摘要:
The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.